Trial Evaluating Cardiovascular Outcomes With Sitagliptin
OVERVIEW
TECOS evaluated the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease.
design
Randomised, placebo-controlled global clinical trial performed in 14,735 patients who were enrolled between 2009 and 2012. TECOS was coordinated jointly by the DTU and the Duke Clinical Research Institute (DCRI) and conducted in 38 countries.
RESULTS
The results of TECOS were reported at the 2015 meeting of the ADA. It met its primary safety endpoint of non-inferiority for the primary composite cardiovascular endpoint of (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalisation for unstable angina). Rates of hospitalization for heart failure, acute pancreatitis and pancreatic cancer did not differ between the two groups. The primary results paper is available here.
manuscript proposals
The TECOS Publications Committee are happy to review proposals for potential new manuscripts. Proposals should be submitted on a TECOS Trial Topic Request Form emailed to peter.hoffmann@duke.edu